TY - JOUR
T1 - In vitro and in vivo antitumor effect of the anti-CD26 monoclonal antibody 1F7 on human CD30+ anaplastic large cell T-cell lymphoma Karpas 299
AU - Aytac, Ugur
AU - McKee, Kathryn S.
AU - Cabanillas, Fernando
AU - Ho, Linus
AU - Neumann, Christopher
AU - Abbruzzese, James L.
AU - Mills, Gordon B.
AU - LaPushin, Ruth
AU - Dang, Nam H.
AU - Stephens, L. Clifton
AU - Ohnuma, Kei
AU - Morimoto, Chikao
PY - 2001
Y1 - 2001
N2 - CD26 is a Mr 110,000 surface glycoprotein with diverse functional properties, including having a potentially significant role in tumor development, and antibodies to CD26 mediate pleomorphic cellular functions. In this report, we show that binding of soluble anti-CD26 monoclonal Ab 1F7 inhibits the growth of the human CD30+ anaplastic large cell T-cell lymphoma cell line Karpas 299 in both in vitro and in vivo experiments. In vitro experiments show that 1F7 induces cell cycle arrest at the G1-S checkpoint, associated with enhanced p21 expression that is dependent on de novo protein synthesis. Furthermore, experiments with a severe combined immunodeficient mouse tumor model demonstrate that 1F7 treatment significantly enhances survival of tumor-bearing mice by inhibiting tumor formation. Our data therefore suggest that anti-CD26 treatment may have potential clinical use for CD26+ hematological malignancies.
AB - CD26 is a Mr 110,000 surface glycoprotein with diverse functional properties, including having a potentially significant role in tumor development, and antibodies to CD26 mediate pleomorphic cellular functions. In this report, we show that binding of soluble anti-CD26 monoclonal Ab 1F7 inhibits the growth of the human CD30+ anaplastic large cell T-cell lymphoma cell line Karpas 299 in both in vitro and in vivo experiments. In vitro experiments show that 1F7 induces cell cycle arrest at the G1-S checkpoint, associated with enhanced p21 expression that is dependent on de novo protein synthesis. Furthermore, experiments with a severe combined immunodeficient mouse tumor model demonstrate that 1F7 treatment significantly enhances survival of tumor-bearing mice by inhibiting tumor formation. Our data therefore suggest that anti-CD26 treatment may have potential clinical use for CD26+ hematological malignancies.
UR - http://www.scopus.com/inward/record.url?scp=0034776255&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034776255&partnerID=8YFLogxK
M3 - Article
C2 - 11448921
AN - SCOPUS:0034776255
VL - 7
SP - 2031
EP - 2040
JO - Clinical Cancer Research
JF - Clinical Cancer Research
SN - 1078-0432
IS - 7
ER -